STOCK TITAN

NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

NeOnc Technologies (NTHI), a clinical-stage biotech company focused on brain and central nervous system cancer treatments, announces a live interview featuring Executive Chairman Amir Heshmatpour with Kenny Polcari on YouTube.com/@Floorstocks on July 23, 2025, at 11:00 a.m. ET.

The interview follows two significant developments: the execution of a Sub-License Agreement with NuroCure for the UAE, GCC, and MENA regions as part of a $50 million strategic partnership with Quazar Investment, and the company's inclusion in the Russell Microcap Index. NeOnc's NEO100™ and NEO212™ therapeutics are currently in Phase II clinical trials with FDA Fast-Track status, targeting malignant gliomas with patent protection until 2038.

NeOnc Technologies (NTHI), un'azienda biotecnologica in fase clinica focalizzata sui trattamenti per il cancro al cervello e al sistema nervoso centrale, annuncia un'intervista in diretta con il Presidente Esecutivo Amir Heshmatpour e Kenny Polcari su YouTube.com/@Floorstocks il 23 luglio 2025 alle 11:00 ET.

L'intervista segue due importanti sviluppi: la firma di un Accordo di Sub-licenza con NuroCure per gli Emirati Arabi Uniti, il GCC e le regioni MENA, parte di una partnership strategica da 50 milioni di dollari con Quazar Investment, e l'inclusione dell'azienda nell'indice Russell Microcap. I farmaci NEO100™ e NEO212™ di NeOnc sono attualmente in fase II di sperimentazione clinica con lo status Fast-Track della FDA, mirati ai gliomi maligni e protetti da brevetto fino al 2038.

NeOnc Technologies (NTHI), una empresa biotecnológica en etapa clínica enfocada en tratamientos para el cáncer cerebral y del sistema nervioso central, anuncia una entrevista en vivo con el Presidente Ejecutivo Amir Heshmatpour y Kenny Polcari en YouTube.com/@Floorstocks el 23 de julio de 2025 a las 11:00 a.m. ET.

La entrevista sigue a dos desarrollos importantes: la ejecución de un Acuerdo de Sub-licencia con NuroCure para los EAU, GCC y regiones MENA como parte de una asociación estratégica de 50 millones de dólares con Quazar Investment, y la inclusión de la compañía en el índice Russell Microcap. Los tratamientos NEO100™ y NEO212™ de NeOnc están actualmente en ensayos clínicos de fase II con estatus Fast-Track de la FDA, dirigidos a gliomas malignos y protegidos por patentes hasta 2038.

NeOnc Technologies (NTHI)는 뇌 및 중추신경계 암 치료에 집중하는 임상 단계의 바이오테크 회사로, 2025년 7월 23일 오전 11시(동부시간)에 YouTube.com/@Floorstocks에서 임원 회장 Amir Heshmatpour와 Kenny Polcari의 라이브 인터뷰를 발표합니다.

이번 인터뷰는 두 가지 중요한 발전 사항 이후에 진행됩니다: UAE, GCC 및 MENA 지역을 대상으로 하는 NuroCure와의 서브 라이선스 계약 체결과 Quazar Investment와의 5,000만 달러 전략적 파트너십의 일환이며, 회사가 Russell Microcap 지수에 포함된 것입니다. NeOnc의 NEO100™ 및 NEO212™ 치료제는 현재 FDA 패스트트랙 지위를 가진 2상 임상시험 중이며, 악성 교모세포종을 대상으로 하고 2038년까지 특허 보호를 받고 있습니다.

NeOnc Technologies (NTHI), une société biotechnologique en phase clinique spécialisée dans les traitements des cancers du cerveau et du système nerveux central, annonce une interview en direct avec le président exécutif Amir Heshmatpour et Kenny Polcari sur YouTube.com/@Floorstocks le 23 juillet 2025 à 11h00 ET.

L'interview fait suite à deux développements importants : la signature d'un accord de sous-licence avec NuroCure pour les régions EAU, GCC et MENA dans le cadre d'un partenariat stratégique de 50 millions de dollars avec Quazar Investment, ainsi que l'inclusion de la société dans l'indice Russell Microcap. Les traitements NEO100™ et NEO212™ de NeOnc sont actuellement en essais cliniques de phase II avec un statut Fast-Track de la FDA, ciblant les gliomes malins et protégés par brevet jusqu'en 2038.

NeOnc Technologies (NTHI), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Behandlungen von Hirn- und Zentralnervensystem-Krebs spezialisiert hat, kündigt ein Live-Interview mit Executive Chairman Amir Heshmatpour und Kenny Polcari auf YouTube.com/@Floorstocks am 23. Juli 2025 um 11:00 Uhr ET an.

Das Interview folgt auf zwei bedeutende Entwicklungen: den Abschluss eines Unterlizenzvertrags mit NuroCure für die VAE, GCC- und MENA-Regionen im Rahmen einer 50-Millionen-Dollar-Strategiepartnerschaft mit Quazar Investment sowie die Aufnahme des Unternehmens in den Russell Microcap Index. Die Therapeutika NEO100™ und NEO212™ von NeOnc befinden sich derzeit in Phase-II-Studien mit FDA-Fast-Track-Status, zielen auf bösartige Gliome ab und sind bis 2038 patentgeschützt.

Positive
  • Strategic partnership worth $50 million with Quazar Investment
  • Inclusion in Russell Microcap Index, potentially increasing institutional investment and liquidity
  • Two drug candidates (NEO100™ and NEO212™) in Phase II trials with FDA Fast-Track status
  • Patent protection extending to 2038 for proprietary technology
Negative
  • Partnership with Quazar Investment not yet finalized
  • Still in clinical-stage with no commercialized products
  • Dependent on successful completion of clinical trials for future growth

Insights

NeOnc's $50M partnership and Russell Microcap inclusion signal positive business development despite interview being a marketing event.

This press release primarily announces an upcoming interview, but contains two significant developments worth noting. NeOnc has executed a Sub-License Agreement with its Abu Dhabi subsidiary NuroCure, marking progress toward a $50 million strategic partnership with Quazar Investment. This agreement covers the UAE, GCC and MENA regions, demonstrating geographical expansion of NeOnc's clinical-stage CNS cancer therapeutics.

Additionally, NeOnc's inclusion in the Russell Microcap Index represents an important capital markets milestone. Such inclusion typically enhances visibility among institutional investors, can drive passive fund inflows, and potentially improve trading liquidity – critical factors for small biotechnology companies.

The company's core value proposition centers on its NEO™ drug development platform targeting the blood-brain barrier, with two candidates (NEO100™ and NEO212™) currently in Phase II clinical trials with FDA Fast-Track designation. Their patent protections extend to 2038, providing substantial runway if therapies prove successful.

While the press release is framed around a marketing event (the interview), the underlying business developments signal positive momentum. However, investors should note the forward-looking statements caution that the Quazar agreement isn't finalized, indicating some execution risk remains in securing the full $50 million partnership.

CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, is pleased to announce that its Executive Chairman & President, Amir Heshmatpour, will be featured in a live interview with prominent financial commentator Kenny Polcari on YouTube.com/@Floorstocks. The interview will air live today at 11:00 a.m. ET.

The interview comes on the heels of NeOnc’s recent execution of a Sub-License Agreement with its Abu Dhabi onshore operating subsidiary, NuroCure, a key milestone toward the company’s $50 million strategic partnership with Quazar Investment. This agreement, which covers the UAE and the broader GCC and MENA regions, reflects NeOnc’s commitment to expanding its footprint and delivering life-saving therapies to patients worldwide.

NeOnc was also recently included in the Russell Microcap Index, a milestone that aligns with the company’s broader capital markets strategy to attract institutional capital, drive passive fund flows, and enhance market liquidity.

“This is an exciting time for NeOnc Technologies as we move closer to closing the $50 million partnership with Quazar Investment and advancing our mission to transform the treatment of brain cancers,” said Amir Heshmatpour, Executive Chairman & President of NeOnc Technologies Holdings, Inc. “We are honored to share our journey and achievements with Kenny Polcari’s and Floorstocks’ audiences.”

ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.



NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.

Important Cautions Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.

Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.

The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.

We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.

“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Company Contact:


info@neonc.com

Investor Contact:


James Carbonara

Hayden IR

(646)-755-7412

James@haydenir.com


FAQ

What is the status of NTHI's partnership with Quazar Investment?

NeOnc Technologies has executed a Sub-License Agreement with NuroCure as part of a $50 million strategic partnership with Quazar Investment, covering UAE, GCC, and MENA regions, though the final agreement is still pending.

What stage are NeOnc Technologies' (NTHI) clinical trials in?

NeOnc's NEO100™ and NEO212™ therapeutics are currently in Phase II human clinical trials and have received FDA Fast-Track status.

When will NTHI's drug patents expire?

NeOnc Technologies' patent portfolio has protection extending to 2038 for NEO100, NEO212, and other products from the NeOnc patent family.

What is the significance of NTHI joining the Russell Microcap Index?

The inclusion in the Russell Microcap Index is expected to attract institutional capital, drive passive fund flows, and enhance market liquidity for NeOnc Technologies.

What types of cancer does NTHI's technology target?

NeOnc Technologies focuses on developing treatments for brain and central nervous system cancers, specifically targeting malignant gliomas through their proprietary chemotherapy agents.
NeOnc Technologies Holdings Inc

NASDAQ:NTHI

NTHI Rankings

NTHI Latest News

NTHI Latest SEC Filings

NTHI Stock Data

79.15M
2.10M
Pharmaceutical Preparations
CALABASAS